Evidence map›Paper›PMID 41322606›Full record

ArticleACS omega2025

Synthesis and Characterization of Highly Stable Fisetin Encapsulated in Lecithin-Chitosan-Savie Nanoparticles.

Hart Monyatovsky, Travis Anderson, Jay L Nadeau

Abstract read
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hart MonyatovskyDepartment of Physics, Portland State University, Portland, Oregon 97201, United States.
Travis AndersonDepartment of Physics, Portland State University, Portland, Oregon 97201, United States.
Jay L NadeauDepartment of Physics, Portland State University, Portland, Oregon 97201, United States.ORCID https://orcid.org/0000-0001-5258-0076

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Senolytic drugs, of the class of polyphenolic flavonoids, have attracted attention for a wide variety of medical applications for which they may be delivered topically, orally, and/or intravenously. However, due to their hydrophobicity and sensitivity to light and oxygen, they have been proven difficult to package and deliver. Here we report a synthesis method for encapsulated fisetin using lecithin-chitosan ionic gelation with a recently reported surfactant that is an alternative to polyethylene glycol (PEG)-containing compounds. Called "Savie" for a contraction of its components, sarcosine-Vitamin E, this surfactant allows for production of sub-100 nm nanoparticles that are bench stable for at least 10 months without aggregation. The environmentally sensitive fluorescence of fisetin allows it to be used as a tool for analysis of particle structure and stability. Absorbance, steady-state fluorescence, and fluorescence lifetime measurements alone and with quenchers indicate that a fraction of the fisetin is accessible to the surface solution and highly photooxidizable, whereas a second fraction is deeply complexed within the particle and significantly more stable. The two fractions may be distinguished from their absorbance peaks. The particles are readily taken up by cultured fibroblasts, with distinct fluorescence lifetimes occurring on the edges vs the interior of the cell. The particles show strong antioxidant activity in cells which is a combination of the effects of fisetin and Vitamin E.

Identifiers

PMID41322606
PMCPMC12658699

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.